Opus Genetics (IRD) Change in Account Payables (2020 - 2026)
Opus Genetics' (IRD) quarterly Change in Account Payables came in at $1.2 million in Q1 2026, up 260.86% year-on-year from $320065.6 in Q1 2025, and up 43.66% on a QoQ basis from $804000.0 in Q4 2025.
Opus Genetics (IRD) Change in Account Payables (2020 - 2026) Analysis & Trends
Opus Genetics (IRD) has 7 years of Change in Account Payables data on file, last reported at $1.2 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 260.86% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 559.66% increase from a year earlier, with the FY2025 full-year figure at $7000.0, down 96.82% from the prior year.
- Change in Account Payables for Q1 2026 stood at $1.2 million, up from $804000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for IRD reached as high as $1.5 million in Q4 2024 and fell as low as -$1.4 million in Q2 2024.
- Historically, Change in Account Payables has averaged $114647.1 across 5 years, with a median of $102000.0 in 2023.
- Across the five-year window, Change in Account Payables soared 23140.0% in 2023 and plunged 1501.96% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at -$390000.0 in 2022, then jumped by 195.64% to $373000.0 in 2023, then jumped by 312.6% to $1.5 million in 2024, then tumbled by 47.76% to $804000.0 in 2025, then surged by 43.66% to $1.2 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $1.2 million in Q1 2026, $804000.0 in Q4 2025, and $906000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 16.86 Mn |
| 10 | Opus Genetics | 263.72 Mn | 203.72 Mn | - | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.16 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 804,000.00 |
| Dec 31, 2025 | 804,000.00 |
| Sep 30, 2025 | 906,000.00 |
| Sep 30, 2025 | 906,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Mar 31, 2025 | -718,000.00 |
| Mar 31, 2025 | -718,000.00 |
| Dec 31, 2024 | 1.54 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | -89,000.00 |
| Mar 31, 2024 | -89,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Dec 31, 2023 | 373,000.00 |